Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Mirror Image who wrote (1856)	4/18/2016 6:03:16 PM
From: Strong Long	Read Replies (1) \| Respond to of 2026

MI as always thanks for digging in and in this case bringing attention to some very key areas expressed in the report. With the sales figures in Europe less than feverish, or at least lower than I thought they would be thus far, I often question whether Allergen would even be interested in US Vitaros marketing rights...provided Apricus gains FDA approval. I also wonder if it would be better if they (Allergen) didn't acquire them. If Vitaros is a good (effective) drug, US approval may be the game changer. Anyone have any thoughts as to why the volume is consistently higher in this lower price range? Is one of our Institutional's getting out? Others getting in? Is Vitaros and the skin permeation enhancer really only worth $0.58?